Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Lancet Oncol
; 18(9): 1202-1210, 2017 09.
Article
in En
| MEDLINE
| ID: mdl-28729151
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antibodies, Monoclonal, Humanized
/
Melanoma
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
America do norte
/
Oceania
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2017
Type:
Article